Europe Chemiluminescence Immunoassay Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 2.09 Bn

Forecast Year, 2035

USD 4.19 Bn

CAGR, 2026 - 2035

7.2%

Report Coverage

Europe

The Europe chemiluminescence immunoassay market size was estimated at USD 2.09 billion in 2025 and is projected to be worth around USD 4.19 billion by 2035, growing at a CAGR of 7.2% from 2026 to 2035. The market is mainly fueled by the rising rates of chronic and infectious diseases, laboratory automation, and diagnostic needs for an aging population.

Europe Chemiluminescence Immunoassay Market Statical Scope

The European Chemiluminescence Immunoassay (CLIA) market is vital as it supports the region's advanced, publicly funded healthcare systems, which focus on standardized disease screening, preventive care, and personalized medicine. CLIA technology is highly sensitive and crucial for the rapid, accurate diagnosis of infectious diseases and cancer markers. Hospital networks in major countries like Germany, France, and the UK are merging to combine CLIA with clinical chemistry on large automated track systems. Increasing cases of cancer and autoimmune diseases, along with a growing elderly population, create a need for high-throughput testing that CLIA analyzers can deliver.

The strict enforcement of regulatory standards demands highly reliable, standardized assays to guarantee accurate diagnoses and patient safety. The widespread use of high-sensitivity diagnostic protocols like high-sensitivity troponin protocols supported by the European Society of Cardiology promotes ongoing improvements to CLIA platforms in hospital emergency departments.

Europe Chemiluminescence Immunoassay Market, By Product, 2025 (%)

• Consumables - In the European Chemiluminescence Immunoassay (CLIA) market, the consumables segment, with a share of 56.40% in 2025, plays a dominant role as it is the main factor behind the industry's large volume. The regular use of reagents, assay kits, and calibrators is essential for the daily operation of highly automated laboratory systems.
• Instruments - The instruments segment, with a share of 29.70% in 2025, serves as the foundation of the European Chemiluminescence Immunoassay (CLIA) market, as it promotes long-term reagent use and supports high-throughput laboratory automation. Advanced analyzers are crucial for European healthcare systems to handle extensive population screening, precision medicine, and the management of complex chronic diseases.
• Software & Services - The software and services segment, with a share of 13.90% in 2025, is important in the Europe Chemiluminescence Immunoassay (CLIA) market due to the digitization of healthcare, laboratory consolidation, and strict regulatory requirements. It allows high-throughput diagnostic networks to automate processes, connect with LIMS, and maintain CE-compliant quality control.

Europe Chemiluminescence Immunoassay Market, By Application, 2025 (%)

• Cardiology - The cardiology segment, with a share of 15.80% in 2025, is significant in the Europe Chemiluminescence Immunoassay (CLIA) market as cardiovascular diseases (CVDs) are a major cause of death in the region. CLIA analyzers are vital for the quick and sensitive detection of important cardiac biomarkers, facilitating timely emergency care, improving patient outcomes, and lowering healthcare expenses.
• Therapeutic Drug Monitoring - The Therapeutic Drug Monitoring (TDM) segment, with a share of 12.60% in 2025, is a key revenue source in the Europe Chemiluminescence Immunoassay (CLIA) market. It is essential as it directly helps precision medicine, ensures the safe management of biologics and chemotherapy, and helps avoid adverse drug reactions that lead to expensive hospital readmissions.

Europe Chemiluminescence Immunoassay Market, By End-use, 2025 (%)

• Clinical Laboratories - The clinical laboratories sector, with a share of 46.80% in 2025, leads the Europe Chemiluminescence Immunoassay (CLIA) Market. These labs are important as they handle large amounts of routine and specialized tests necessary for public health monitoring, managing chronic diseases, and preventive care.
• Hospitals - The hospital sector, with a share of 33.40% in 2025, is the fastest-growing end-user group in the Europe Chemiluminescence Immunoassay (CLIA) Market. This segment is crucial as hospitals generate high, ongoing testing volumes for chronic and infectious diseases, use standardized automation, maintain long-term supply agreements, and require rapid diagnostic results.

Competitive Landscape

The European Chemiluminescence Immunoassay (CLIA) market is a highly competitive and consolidated sector, primarily led by multinational diagnostics companies. The market is fueled by the increasing need for high-sensitivity biomarker detection and automated processes, relying on major regional players who provide both high-throughput automated analyzers and specialized reagent panels to clinical labs.

• Roche Diagnostics (Switzerland) is the market leader with its Elecsys immunoassay systems, including the high-throughput cobas e 801 analyzer and a range of assays for infectious diseases and oncology.
• Abbott Laboratories (USA) is recognized for its Alinity i and ARCHITECT platforms, which offer high-speed, continuous-access testing for endocrinology, cardiology, and infectious diseases.
• Siemens Healthineers (Germany) provides the Atellica Solution and ADVIA Centaur platforms, known for their automated, smart-routing technology that improves laboratory efficiency.
• Beckman Coulter / Danaher (USA) offers the Access series of immunoassay systems, featuring a wide range of tests for autoimmune and reproductive diagnostics.
• DiaSorin (Italy) focuses on niche and specialty testing with the LIAISON family of analyzers, commonly used in Europe for bone metabolism and infectious serology.
• bioMérieux (France) emphasizes infectious disease and sepsis testing, utilizing automated systems like the VIDAS family.
• Mindray (China) is quickly growing its presence in European mid-sized labs with the CL-series (e.g., CL-900i and CL-1200i).
• Snibe (China) is known for the MAGLUMI series, which provides fully automated, cost-effective analyzers for emerging markets and decentralized hospital testing.

Segments Covered in the Report

By Product

• Consumables
• Instruments
• Software & Services

By Application

• Cardiology
• Therapeutic Drug Monitoring
• Oncology
• Endocrinology
• Autoimmune Disease
• Infectious Disease
• Others

By End-use

• Clinical Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Others